Transaction DateRecipientSharesTypePriceValue
18th December 2020Daniel F Voytas5,026Open or private sale$4.75$23,873.50
2nd November 2020Travis Frey150Open or private purchase$3.26$489.33
16th October 2020S.A. Cellectis1,250,000Other acquisition or disposition$4.00$5,000,000.00
1st October 2020Travis Frey150Open or private purchase$5.47$820.10
30th September 2020James Blome4,140Open or private sale$5.59$23,123.56
10th September 2020Philippe Dumont3,000Open or private purchase$5.91$17,728.80
1st September 2020Travis Frey150Open or private purchase$5.41$811.01
14th August 2020Philippe Dumont2,000Open or private purchase$7.49$14,970.40
3rd August 2020Travis Frey150Open or private purchase$4.36$653.90
2nd July 2020Philippe Dumont236Open or private sale$4.70$1,109.20
Calyxt
Calyxt logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.


Calyxt is a healthy food ingredient company. The company was founded by Daniel F. Voytas and André Choulika on January 8, 2010.


Ticker: CLXT
Sector: Commercial Services
Industry: Miscellaneous Commercial Services
SEC Central Index Key (CIK): 1705843
Employees: 75
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $4 M (0%)
Inventory, Net: $5 M (0%)
Assets, Current: $44 M (-30%)
Property, Plant and Equipment, Net: $23 M (-2%)
Other Assets, Noncurrent: $427 Th (31%)
Assets: $68 M (-22%)
Accounts Payable, Current: $572 Th (-46%)
Accrued Liabilities, Current: $2 M (-21%)
Liabilities, Current: $5 M (-35%)
Other Liabilities, Noncurrent: $132 Th (-12%)
Liabilities: $24 M (-4%)
Common Stock, Value, Issued: $3 Th (0%)
Common Stock, Shares, Issued: $33 M (0%)
Additional Paid in Capital, Common Stock: $189 M (1%)
Retained Earnings (Accumulated Deficit): $144 M (17%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $41 Th (141%)
Stockholders' Equity (Parent): $44 M (0%)
Liabilities and Equity: $68 M (-22%)
Revenue: $2 M (-50%)
Cost of Revenue: $5 M (-42%)
Gross Margin: $3 M (-33%)
Research and Development: $3 M (-49%)
Sales and Marketing: $1 M (-53%)
General and Administrative Expenses: $4 M (-55%)
Operating Income/Loss: $11 M (-49%)